文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克患者肾上腺皮质候选基因表达与氢化可的松临床反应的关系

The relationship between adrenocortical candidate gene expression and clinical response to hydrocortisone in patients with septic shock.
PubMed 文献 · Intensive Care Med · 2021-06-29
一句话结论脓毒性休克中肾上腺皮质候选基因表达与死亡率无关,但GLCCI1与BHSD1表达和氢化可的松对休克逆转时间的效应存在交互作用。

该研究为一项氢化可的松对比安慰剂治疗脓毒性休克随机对照试验的预设巢式队列研究,2014年5月至2017年4月共纳入671例患者,其中494份样本可用于RNAseq分析,检测与垂体释放激素、盐皮质激素和糖皮质激素受体、细胞内糖皮质激素代谢及转运蛋白相关的肾上腺皮质候选基因表达。结果未发现候选基因表达水平与90天死亡率、28天死亡率或休克逆转时间相关;但GLCCI1(交互作用p=0.008)和BHSD1(交互作用p=0.01)的表达与治疗分组对休克逆转时间存在显著交互作用。结论认为脓毒性休克患者肾上腺皮质候选基因表达与死亡率无关,GLCCI1高表达者接受氢化可的松后休克逆转快于安慰剂组,而BHSD1高表达者接受氢化可的松后休克逆转慢于安慰剂组,基因表达变异可能是皮质类固醇治疗反应异质性的机制。

要点

  • 巢式队列共纳入671例脓毒性休克患者,494份样本可行RNAseq分析,未发现候选基因表达与90天死亡率、28天死亡率或休克逆转时间相关。
  • GLCCI1表达与治疗分组对休克逆转时间存在交互作用(p=0.008):氢化可的松组HR 3.81(95%CI 0.57-25.47),安慰剂组HR 0.64(95%CI 0.13-3.07)。
  • BHSD1表达与治疗分组对休克逆转时间存在交互作用(p=0.01):氢化可的松组HR 0.55(95%CI 0.28-1.09),安慰剂组HR 1.32(95%CI 0.67-2.60)。
  • GLCCI1高表达者接受氢化可的松后休克逆转快于安慰剂组,BHSD1高表达者接受氢化可的松后休克逆转慢于安慰剂组。
  • 作者认为基因表达变异可能是脓毒性休克中皮质类固醇治疗反应异质性的机制。

适用人群与场景

  • 脓毒性休克患者,来自一项氢化可的松对比安慰剂的随机对照试验,为预设巢式队列研究。
  • 2014年5月至2017年4月共671例患者纳入巢式队列研究,其中494份样本可用于分析。
  • 在氢化可的松或安慰剂治疗前采集血样进行RNAseq分析。

研究设计与关键结果

  • 研究类型:随机对照试验的预设巢式队列研究;2014年5月至2017年4月纳入671例,494份样本行RNAseq分析。
  • 未发现候选基因表达水平与90天死亡率、28天死亡率或休克逆转时间相关的证据。
  • GLCCI1表达与治疗分组对休克逆转时间存在显著交互作用:氢化可的松组HR 3.81(95%CI 0.57-25.47)vs 安慰剂组HR 0.64(95%CI 0.13-3.07),交互作用p=0.008。
  • BHSD1表达与治疗分组对休克逆转时间存在显著交互作用:氢化可的松组HR 0.55(95%CI 0.28-1.09)vs 安慰剂组HR 1.32(95%CI 0.67-2.60),交互作用p=0.01。
  • GLCCI1高表达者接受氢化可的松后休克逆转快于安慰剂组;BHSD1高表达者接受氢化可的松后休克逆转慢于安慰剂组。

证据类型、等级与局限

  • 证据类型:随机对照试验的预设巢式队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为基因表达变异可能是脓毒性休克中皮质类固醇治疗反应异质性的机制,提示未来或可据此识别可能从氢化可的松获益的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To determine if adrenocortical gene expression is associated with clinical outcomes or response to corticosteroid treatment in septic shock.

METHODS: A pre-specified nested cohort study of a randomised controlled trial of hydrocortisone compared to placebo in septic shock. Blood was collected for RNAseq analysis prior to treatment with hydrocortisone or placebo. The expression of adrenocortical candidate genes related to pituitary releasing hormones, mineralocorticoid and glucocorticoid receptors, intracellular glucocorticoid metabolism and transport proteins was measured.

RESULTS: From May 2014 to April 2017, 671 patients were enrolled in the nested cohort study, from which 494 samples were available for analysis. We found no evidence of an association between candidate gene expression levels and either 90-day mortality, 28-day mortality or time to shock reversal. We observed evidence of a significant interaction between expression and treatment group for time to shock reversal in two genes; GLCCI1 (HR 3.81, 95%CI 0.57-25.47 vs. HR 0.64, 95%CI 0.13-3.07 for hydrocortisone and placebo respectively, p for interaction 0.008) and BHSD1 (HR 0.55, 95%CI 0.28-1.09 vs. HR 1.32 95%CI 0.67-2.60, p for interaction 0.01).

CONCLUSIONS: In patients with septic shock, there is no association between adrenocortical candidate gene expression and mortality. Patients with higher expression of GLCCI1 who received hydrocortisone achieved shock resolution faster than those receiving placebo; conversely, patients who had higher expression of BHSD1 who received hydrocortisone achieved shock resolution slower than those who received placebo. Variation in gene expression may be a mechanism for heterogeneity of treatment response to corticosteroids in septic shock.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Cohen J, Blumenthal A, Cuellar-Partida G, et al. The relationship between adrenocortical candidate gene expression and clinical response to hydrocortisone in patients with septic shock. Intensive Care Med. 2021. PMID: 34185116. doi:10.1007/s00134-021-06464-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。